Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...
Objective Heart failure (HF) is common with high associated morbidity and mortality. UK National Institute for Health and ...
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...
Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...
Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.
Pharmaceutical Technology on MSN
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with symptomatic obstructive ...
EXCLUSIVE: PowerPoints from lectures in an introductory education course at the University of Illinois Urbana-Champaign are riddled with far-left lessons teaching future educators to view their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback